Skip to main content
Hanshang Group Co.,Ltd. logo

Hanshang Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600774 ISIN · CNE000000NC5 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,577 across all filing types
Latest filing 2020-09-23 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600774

About Hanshang Group Co.,Ltd.

https://www.whhsg.com/

Hanshang Group Co.,Ltd. is a diversified enterprise focused on commercial operations, exhibition services, and healthcare. The company manages a portfolio of large-scale department stores, shopping malls, and specialized retail outlets. Its exhibition segment provides comprehensive venue management and event organization services for international and domestic trade fairs. Hanshang Group has significantly expanded its presence in the healthcare sector through the development and distribution of pharmaceuticals, medical devices, and health-related products. By integrating traditional commercial assets with modern biomedical research and health management services, the group targets a broad consumer base and professional medical markets, emphasizing a strategic transition toward a comprehensive health-oriented business model.

Recent filings

Filing Released Lang Actions
董事会关于评估机构的独立性、评估假设前提的合理性、评估方法与评估目的的相关性以及评估定价的公允性的意见
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of 汉商集团股份有限公司 regarding the independence of the appraisal agency, the reasonableness of appraisal assumptions, the relevance of appraisal methods to the appraisal purpose, and the fairness of appraisal pricing. It relates to a major asset purchase transaction involving the acquisition of 100% shares of 成都迪康药业股份有限公司. The document discusses the evaluation process and fairness opinion but does not contain financial statements or detailed financial results. It is a formal opinion or announcement related to a transaction, specifically focusing on appraisal and valuation fairness. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about the appraisal opinion for a transaction, not a full report or financial statement, nor a merger filing or capital update.
2020-09-23 Chinese
中信建投证券股份有限公司关于汉商集团股份有限公司本次交易前十二个月内购买、出售资产情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from an independent financial advisor regarding asset purchase and sale activities of a listed company within twelve months prior to a major asset restructuring. It references regulatory guidelines related to major asset restructuring and confirms no related asset transactions need to be cumulatively calculated for the current transaction. The document is a standalone audit or verification report related to a major asset restructuring, not the restructuring report itself or an announcement of a report. It contains specific findings and opinions from the independent financial advisor, fitting the definition of an Audit Report / Information (AR). The document length is short but contains substantive content, not merely an announcement or certification letter, so it is not RPA or RNS. Q3 2020
2020-09-23 Chinese
中信建投证券股份有限公司关于汉商集团股份有限公司股票价格波动是否达到《关于规范上市公司信息披露及相关各方行为的通知》第五条相关标准的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from an independent financial advisor (中信建投证券股份有限公司) regarding whether the stock price fluctuation of 汉商集团股份有限公司 meets the criteria set out in a regulatory notice (证监公司字〔2007〕128号) related to significant stock price movements before disclosure of major information. It includes analysis of stock price changes relative to market indices and concludes that the stock price fluctuation did not exceed the regulatory threshold. The document is a specialized regulatory compliance opinion or verification rather than a financial report, earnings release, or announcement of voting results. It does not contain financial statements or earnings data, nor is it a report publication announcement. It is best classified as a Regulatory Filing (RNS) because it is a regulatory compliance document that does not fit other categories.
2020-09-23 Chinese
备考合并财务报表审阅报告
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial statements including balance sheets, income statements, and notes for the period ending June 30, 2020, and comparative figures for December 31, 2019. It includes comprehensive financial data such as assets, liabilities, equity, revenues, expenses, and earnings per share. The length of the document is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. The presence of half-year financial data (2020年1-6月) indicates this is an interim or quarterly report rather than a full annual report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2020-09-23 Chinese
成都迪康药业股份有限公司审计报告
Annual Report Classification · 95% confidence The document contains detailed financial data including assets, liabilities, equity, and notes references, typical of comprehensive financial statements. The length is substantial (15,000 characters), indicating it is not a brief announcement. The presence of multiple financial line items and notes suggests this is part of a full financial report rather than a summary or announcement. There is no indication that this is a certification, proxy, or voting result. The document appears to be a full financial report for a fiscal period, consistent with an Annual Report (10-K) or possibly an Interim/Quarterly Report (IR). However, the presence of multiple years and detailed notes suggests a full annual report rather than a quarterly report. Therefore, the most appropriate classification is Annual Report (10-K).
2020-09-23 Chinese
重大资产购买报告书（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is titled "重大资产购买报告书（草案）摘要" which translates to "Major Asset Purchase Report (Draft) Summary". It details a significant asset acquisition transaction by 汉商集团股份有限公司 (Hanshang Group Co., Ltd.), including transaction parties, asset valuation, payment arrangements, legal and financial advisor involvement, and regulatory compliance. The content includes detailed financial data, transaction structure, approvals, and risk disclosures related to a major asset purchase. This aligns with filings related to major asset acquisitions or restructuring rather than a general annual report or earnings release. The document is comprehensive and contains substantive financial and transaction details, not merely an announcement or summary. According to the filing definitions, this fits best under "Capital/Financing Update (CAP)" as it provides updates on company financing activities and capital structure changes related to a major asset purchase. It is not a full annual report (10-K), audit report (AR), or merger proxy statement (MA), but a detailed report on a significant capital transaction. Therefore, the classification is CAP with high confidence.
2020-09-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.